Moss Adams Wealth Advisors LLC Has $758,000 Stake in Danaher Co. (NYSE:DHR)

Moss Adams Wealth Advisors LLC reduced its stake in shares of Danaher Co. (NYSE:DHR) by 2.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,272 shares of the conglomerate’s stock after selling 75 shares during the quarter. Moss Adams Wealth Advisors LLC’s holdings in Danaher were worth $758,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. BKM Wealth Management LLC acquired a new position in Danaher in the fourth quarter worth $27,000. Wetzel Investment Advisors Inc. bought a new stake in Danaher during the 4th quarter worth about $29,000. OFI Invest Asset Management acquired a new stake in Danaher in the 3rd quarter valued at about $30,000. Rakuten Securities Inc. bought a new position in shares of Danaher in the fourth quarter worth about $36,000. Finally, Financial Connections Group Inc. acquired a new position in shares of Danaher during the fourth quarter worth approximately $41,000. 79.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DHR. Royal Bank of Canada lifted their target price on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Raymond James upped their target price on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and raised their target price for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. TD Cowen boosted their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Barclays raised their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.31.

Danaher Stock Up 0.3 %

Shares of DHR traded up $0.82 on Wednesday, hitting $249.58. The company’s stock had a trading volume of 1,471,344 shares, compared to its average volume of 2,730,175. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $184.86 billion, a price-to-earnings ratio of 42.30, a P/E/G ratio of 3.82 and a beta of 0.83. The firm’s fifty day moving average price is $248.27 and its 200-day moving average price is $233.19. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.36 earnings per share. On average, equities research analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Transactions at Danaher

In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders sold 103,984 shares of company stock valued at $25,997,094 over the last three months. Company insiders own 10.90% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.